Invests in
Sectors:
Locations:
Min Investment:
$20,000,000.00Max Investment:
$30,000,000.00Target Investment:
$25,000,000.00
Skills
Education
Lists including Aaron
Investments
Marea Therapeutics
Total Funding: $260M
Attovia Therapeutics
Total Funding: $170M
Ceptur Therapeutics
Total Funding: $75M
Ablaze Pharmaceuticals
Total Funding: $75M
HistoWiz
Total Funding: $32M
INBRACE
Total Funding: $150M
Neurogastrx
Total Funding: $110M
RayzeBio
Total Funding: $420M
Ventyx Biosciences
Total Funding: $110M
Akero Therapeutics
Total Funding: $140M
Work Experience
2015
Managing Partner
2015
venBio is a life science venture capital firm that focuses on novel therapeutics for unmet medical needs. Since inception in 2011, venBio has raised nearly $1.5 billion in capital commitments and led investment rounds in 35+ companies, including: Labrys Biologics (acquired by Teva); ALX Oncology (NASDAQ: ALXO); Aragon Pharmaceuticals (acquired by Johnson & Johnson); Seragon Pharmaceuticals (acquired by Roche); Aurinia Pharmaceuticals (NASDAQ: AUPH); Apellis Pharmaceuticals (NASDAQ: APLS); Turning Point Therapeutics (NASDAQ: TPTX, acquired by BMS); Precision Biosciences (NASDAQ: DTIL); Akero Therapeutics (NASDAQ: AKRO); Harmony Biosciences (NASDAQ: HRMY); Pharvaris (NASDAQ: PHVS); Ventyx Biosciences (NASDAQ: VTYX); CinCor Pharma (NASDAQ: CINC, acquired by AstraZeneca), and RayzeBio (NASDAQ: RYZB, acquired by BMS).
2023
Board of Directors
2023
2022
Board of Directors
2022
2021
Board of Directors
2021
2021
Board of Directors
2021
2017
Board Of Directors
2017
2020 - 2023
Board of Directors
2020 - 2023
IPO in September 2023 (NASDAQ: RYZB) Acquired by Bristol Myers Squibb in December 2023 for $4.1B
2021 - 2023
Board of Directors
2021 - 2023
IPO in October 2021 (NASDAQ: VTYX)
2017 - 2020
Board Of Directors
2017 - 2020
IPO in August 2020 (NASDAQ: HRMY) FDA approvals for Wakix in Aug 2019, Oct 2020, and Jun 2024.
2018 - 2019
Board Of Directors
2018 - 2019
IPO in June 2019 (NASDAQ: AKRO)